

North Carolina Division of Medical Assistance

North Carolina Medicaid and Health Choice

Preferred Drug List (PDL)

Trial and failure of two preferred agents are required unless otherwise indicated

Not all therapeutic classes are included on the PDL. Classes not on the PDL are considered preferred.

Prior authorization list, criteria, and forms located at: www.nctracks.nc.gov

For more information on the PDL Process: <http://www.ncdhhs.gov/dma/pharmacy/index.htm>

RECOMMENDED CHANGES post PDL Panel Meeting held Sept. 2015

ANALGESICS

NARCOTIC ANALGESICS

Long Acting

Clinical criteria apply

Preferred

Non-Preferred

Butrans® Patch

Embeda® ER Capsule

fentanyl patch 12mcg / 25mcg / 50mcg / 75mcg / 100mcg (generic for Duragesic®)

Kadian® Capsule

morphine sulfate ER tablet (generic for MS Contin®)

OxyContin® Tablet

Avinza® Capsule

Butrans® Patch

Duragesic® Patch

Exalgo® Tablet

fentanyl patch (37.5 / 62.5 / 87.5mcg dosages)

hydromorphone ER tablet (generic for Exalgo®)

Hysingla® ER Tablet

morphine sulfate ER capsule (generic for Avinza®, Kadian®)

MS Contin® Tablet

Nucynta® ER Tablet

Opana® ER Tablet

oxycodone ER tablet (generic for OxyContin®)

oxymorphone ER tablet (generic for Opana® ER)

Xartemis® XR Tablet

Zohydro® Capsule

MISCELLANEOUS

IMMUNOMODULATORS, SYSTEMIC

Clinical criteria apply

Preferred

Non-Preferred

Trial and failure of only 1 preferred agent required

Enbrel® Kit / Sureclick Syringe / Syringe (TNF Blocker)

Humira® Crohn's Starter Pack / Pediatric Crohn's Starter Pack / Pen / Psoriasis Starter Pack / Syringe (TNF blocker)

Actemra® Syringe / Vial (IL-6 receptro antagonist)

Cimzia® Starter Kit / Syringe Kit / Vial Kit (TNF Blocker)

Cosentyx® Pen / Syringe (IL-17A antagonist)

Entyvio® Vial (Integrin Receptor Antagonist)

Orencia® SQ Syringe (Selective T cell costimulation modulator)

Otezla® Starter Pack / Tablet (PDE4 Inhibitor)

Simponi® Aria Vial / Pen Injector / Syringe (TNF Blocker)

Stelara® Syringe (IL-12 and IL-23 antagonist)

Xeljanz® Tablet (JAKs Inhibitor)

Exemption for Diagnosis of Neonatal Onset: Multi-System Inflammatory Disease

Kineret® Syringe (IL-1 receptor antagonist)